These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 21641471)
21. The ongoing regulation of generic drugs. Frank RG N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956 [No Abstract] [Full Text] [Related]
22. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma. Wang Z Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001 [No Abstract] [Full Text] [Related]
23. FDA chief attacks Canada's drug price controls. Webster P Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624 [No Abstract] [Full Text] [Related]
24. Pharmaceutical industry. Lewis L State Health Care Am; 1994; ():23-7. PubMed ID: 10133845 [TBL] [Abstract][Full Text] [Related]
25. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process. Binzak BA Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592 [No Abstract] [Full Text] [Related]
26. Improving the PPI sample for prescription pharmaceuticals. Kelly GG Mon Labor Rev; 1997 Oct; 120(10):10-7. PubMed ID: 10176326 [No Abstract] [Full Text] [Related]
27. The decreased number of new drug approvals (NDAs) has been a topic of considerable debate over the past decade. Preface. Enna SJ; Williams M Adv Pharmacol; 2009; 57():xi-ii. PubMed ID: 19945649 [No Abstract] [Full Text] [Related]
28. 'We should question the power of drug companies'. Radcliff M Nurs Times; 2008 Jul 8-14; 104(27):52. PubMed ID: 18683392 [No Abstract] [Full Text] [Related]
29. [Development of new drugs is too expensive]. Andreasen J Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066 [No Abstract] [Full Text] [Related]
30. Asymmetric assessments in valuing pharmaceutical risks. Viscusi WK; Magat WA; Scharff R Med Care; 1996 Dec; 34(12 Suppl):DS34-47. PubMed ID: 8969313 [No Abstract] [Full Text] [Related]
31. Drugs with breakthrough status charm investors. Senior M Nat Biotechnol; 2013 Nov; 31(11):945-7. PubMed ID: 24213748 [No Abstract] [Full Text] [Related]
32. Drug companies should release data from all trials of licensed drugs, say MPs. Hawkes N BMJ; 2013 Jan; 346():f321. PubMed ID: 23325880 [No Abstract] [Full Text] [Related]
33. Drug trials: non-medical, non-pharmacological, non-psychiatric and non-psychological considerations. Amatu HI Niger Med J; 1979; 9(7-8):759-65. PubMed ID: 543314 [No Abstract] [Full Text] [Related]
34. Expensive cancer therapies: unintended effects. Delude CM J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602 [No Abstract] [Full Text] [Related]
35. Cutting the cost of drug development? Rawlins MD Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531 [No Abstract] [Full Text] [Related]